Wedbush Forecasts Strong Price Appreciation for WAVE Life Sciences (NASDAQ:WVE) Stock

Key Points

• Wedbush raised its price target on WAVE to $35 and maintained an "outperform" rating, implying roughly 168% potential upside from recent share levels.
• Institutional investors have materially increased positions (notably GSK’s ~$310M stake, Adage and Price T. Rowe additions), driving about 89.7% institutional ownership, while insiders sold roughly $14.1M of stock last quarter and the company reported a recent EPS miss with deep negative margins.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) had its price objective hoisted by stock analysts at Wedbush from $33.00 to $35.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an "outperform" rating on the stock. Wedbush's price target would suggest a potential upside of 168.01% from the company's previous close.

A number of other equities analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of WAVE Life Sciences from a "hold" rating to a "sell" rating in a report on Saturday, February 7th. Cantor Fitzgerald increased their target price on shares of WAVE Life Sciences from $34.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, February 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of WAVE Life Sciences in a research report on Wednesday, January 21st. Leerink Partners restated an "outperform" rating on shares of WAVE Life Sciences in a report on Monday, December 8th. Finally, Citigroup raised their price objective on WAVE Life Sciences from $16.00 to $30.00 and gave the company a "buy" rating in a research note on Tuesday, December 9th. Thirteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $33.13.

WAVE Life Sciences Price Performance

Shares of NASDAQ WVE opened at $13.06 on Friday. WAVE Life Sciences has a 1-year low of $5.28 and a 1-year high of $21.73. The stock has a fifty day moving average price of $14.09 and a 200 day moving average price of $10.92. The company has a market cap of $2.46 billion, a PE ratio of -10.70 and a beta of -1.77.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.02). The firm had revenue of $17.25 million during the quarter, compared to analyst estimates of $15.68 million. WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. Analysts anticipate that WAVE Life Sciences will post -1.14 earnings per share for the current fiscal year.

Insider Transactions at WAVE Life Sciences

In related news, CFO Kyle Moran sold 3,588 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $48,258.60. Following the sale, the chief financial officer owned 134,385 shares of the company's stock, valued at $1,807,478.25. This trade represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Chris Francis sold 33,194 shares of the business's stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $15.05, for a total transaction of $499,569.70. Following the completion of the transaction, the insider directly owned 61,867 shares of the company's stock, valued at $931,098.35. The trade was a 34.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 948,375 shares of company stock worth $14,112,151 in the last quarter. Insiders own 23.98% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. GSK plc acquired a new stake in WAVE Life Sciences in the 4th quarter worth about $310,177,000. Adage Capital Partners GP L.L.C. increased its holdings in WAVE Life Sciences by 20.0% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company's stock valued at $97,607,000 after purchasing an additional 2,500,000 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in WAVE Life Sciences by 83.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company's stock worth $125,927,000 after acquiring an additional 3,362,880 shares in the last quarter. Darwin Global Management Ltd. acquired a new stake in WAVE Life Sciences during the 4th quarter valued at $125,168,000. Finally, Federated Hermes Inc. increased its position in shares of WAVE Life Sciences by 26.5% during the fourth quarter. Federated Hermes Inc. now owns 4,744,520 shares of the company's stock worth $80,657,000 after acquiring an additional 993,827 shares during the last quarter. 89.73% of the stock is currently owned by institutional investors and hedge funds.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.